Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 46
Summary
- Conditions
- Cancer of Head and Neck
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Cancer
- Neoplasms, Head and Neck
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma Head and Neck
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02296684
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Douglas R Adkins, M.D. Washington University School of Medicine